Date published: 2026-5-30

1-800-457-3801

SCBT Portrait Logo
Seach Input

DNCLI2 Inhibitors

DNCLI2 inhibitors are a class of chemical compounds designed to target and inhibit DNCLI2, also known as dynein light chain 1, an essential component of the cytoplasmic dynein motor complex. Dynein motors are responsible for the transport of various cellular cargoes along microtubules, playing a crucial role in processes like intracellular trafficking, organelle positioning, and mitotic spindle orientation during cell division. DNCLI2, as part of the dynein complex, facilitates the interaction between dynein and its cargo by binding to specific adaptor proteins or cargo-binding subunits. By inhibiting DNCLI2, these compounds interfere with the dynein motor function, leading to disruptions in intracellular transport and associated cellular processes.

Structurally, DNCLI2 inhibitors are typically designed to disrupt the binding interactions between DNCLI2 and its partner proteins within the dynein complex or between DNCLI2 and the cargo itself. This inhibition can occur through competitive binding at the protein-protein interaction sites or by allosteric inhibition, where the compound induces conformational changes that reduce the functional capacity of DNCLI2. The inhibition of DNCLI2 allows researchers to explore its specific role within the broader dynein complex and understand how its regulation affects the directional movement of cellular components along microtubules. Additionally, these inhibitors are useful tools for studying the mechanisms behind intracellular transport, providing insight into how motor proteins and their accessory subunits work together to maintain cellular organization and ensure the proper distribution of organelles, vesicles, and other essential cargo throughout the cell.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$26.00
$119.00
$213.00
27
(1)

Inhibits certain tyrosine kinases, which may alter signaling pathways that DNCLI2 is a part of.

Palbociclib

571190-30-2sc-507366
50 mg
$321.00
(0)

Inhibits CDK4/6, potentially affecting the cell cycle and indirectly DNCLI2's role in cell proliferation.

MG-132 [Z-Leu- Leu-Leu-CHO]

133407-82-6sc-201270
sc-201270A
sc-201270B
5 mg
25 mg
100 mg
$60.00
$265.00
$1000.00
163
(3)

Proteasome inhibitor that can affect protein degradation pathways, potentially influencing DNCLI2 levels.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

Inhibits PI3K, possibly affecting DNCLI2's involvement in cell survival pathways.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$63.00
$158.00
$326.00
233
(4)

Inhibits mTOR, which may affect protein synthesis and autophagy, indirectly influencing DNCLI2 activity.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$90.00
$349.00
284
(5)

Inhibits p38 MAPK, potentially affecting stress response pathways linked to DNCLI2.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

Inhibits JNK, which may impact apoptosis pathways where DNCLI2 is potentially involved.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$135.00
$1085.00
115
(2)

Inhibits proteasome, affecting protein turnover, potentially impacting DNCLI2 stability.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$70.00
$145.00
51
(1)

Inhibits Src family kinases, potentially altering signaling pathways involving DNCLI2.

Suberoylanilide Hydroxamic Acid

149647-78-9sc-220139
sc-220139A
100 mg
500 mg
$133.00
$275.00
37
(2)

HDAC inhibitor, potentially affecting gene expression and protein activity related to DNCLI2.